Perrigo Company PLC (PRGO)
| Market Cap | 6.02B |
| Revenue (ttm) | 5.10B |
| Net Income (ttm) | -6.60M |
| Shares Out | 136.50M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | 10.28 |
| Dividend | $0.90 |
| Dividend Yield | 2.02% |
| Trading Day | January 28 |
| Last Price | $44.46 |
| Previous Close | $44.11 |
| Change ($) | 0.35 |
| Change (%) | 0.78% |
| Day's Open | 44.14 |
| Day's Range | 44.04 - 44.81 |
| Day's Volume | 63,165 |
| 52-Week Range | 40.13 - 59.79 |
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...
We believe that Perrigo stock, a healthcare company that provides over-the-counter health and wellness solutions, is a good buying opportunity at the present time. PRGO stock trades near $45 c...
Let's see if Perrigo Company plc (PRGO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
In its journey to become a consumer-led player, Perrigo has already achieved its long-term sales targets well ahead of the schedule. Partly helped by pandemic-driven changes to consumer habits...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our i...
Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales.
The healthcare company delivered both good news and bad news.
Perrigo Company plc (PRGO) CEO Murray Kessler on Q3 2020 Results - Earnings Call Transcript
Perrigo (PRGO) delivered earnings and revenue surprises of 10.71% and -1.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, Nov. 4, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that the Irish High Court, which is a court of first instance, ruled that the issuance of the Notice...
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that it has completed the acqu...
DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has been advised by the Iris...
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that its Board of Directors d...
DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its third quart...
These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.
Perrigo Company plc shares PRGO, -0.16% slid 3% in premarket trade Thursday, after the company said it's voluntarily recalling albuterol sulfate inhalation aerosols over concerns that some may...
DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S.
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
DUBLIN, Ireland, Aug. 25, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that CEO and Preside...
Perrigo Company plc (PRGO) CEO Murray Kessler on Q2 2020 Results - Earnings Call Transcript
Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.
Perrigo (PRGO) delivered earnings and revenue surprises of 18.39% and -0.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Perrigo (NYSE:PRGO) rose 0.9% in pre-market trading after the company reported Q2 results.
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rotation offers opportunity in top stocks and industries.
Medical Products Industry's Near-Term Outlook Lacks Spark
Perrigo Company PLC (NYSE: PRGO), one of the world’s largest producers of over-the-counter self-care products, is entering the CBD business.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
PRGO can effectively and cost efficiently produce generic drugs, competing with brand names.
Perrigo Company plc (PRGO) CEO Murray Kessler on Q1 2020 Results - Earnings Call Transcript
Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.
Perrigo (PRGO) delivered earnings and revenue surprises of 4.59% and 1.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Perrigo (PRGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharmaceuticals company Perrigo CEO says 'all trends are heading toward self-care'
errigo CEO Murray Kessler in a "Mad Money" interview discusses trends in the health-care industry and "transforming ourselves to a self-care company."
Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.
Perrigo Co. PRGO, -1.03% said late Tuesday it experienced a first-quarter sales boost due to the COVID-19 pandemic.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
Medical Products Industry Outlook: Growth Prospects Bright
Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter.
Perrigo Company plc (PRGO) CEO Murray Kessler on Q4 2019 Results - Earnings Call Transcript
Perrigo (PRGO) delivered earnings and revenue surprises of -2.75% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Perrigo Co. PLC PRGO, +0.00% reported Thursday a fourth-quarter adjusted profit that came up shy of expectations while sales were in line, while providing a downbeat full-year earnings outlook.
Perrigo Co (NYSE: PRGO) announces its next round of earnings this Thursday, February 27.
About PRGO
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health,... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Dec 16, 1991 |
| CEO Murray Kessler | Employees 11,000 |
| Stock Exchange NYSE | Ticker Symbol PRGO |
Financial Performance
In 2019, Perrigo's revenue was $4.84 billion, an increase of 2.23% compared to the previous year's $4.73 billion. Earnings were $146.10 million, an increase of 11.53%.
Analyst Forecasts
According to 11 analysts, the average rating for Perrigo stock is "Buy." The 12-month stock price forecast is 56.22, which is an increase of 26.46% from the latest price.